Inhibitors of articular calcium crystal formation

Current Opinion in Rheumatology

Volumn 15, Issue 3, 2003, Pages 321-325

  Sallis, John D ^a   Cheung, Herman S ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Miami College of Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CARBOXYLIC ACID; CITRIC ACID; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPHOSPHATE; SODIUM; STEROID;

ANIMAL MODEL; CALCIFICATION; COMPUTER MODEL; CRYSTAL STRUCTURE; CRYSTALLIZATION; GENETICS; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; STEROID THERAPY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CALCIUM PHOSPHATES; CALCIUM PYROPHOSPHATE; CARTILAGE, ARTICULAR; CHONDROCALCINOSIS; CRYSTALLIZATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; OSTEOARTHRITIS; PROGNOSIS; RATS; RISK FACTORS;

EID: 0037732604     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200305000-00022     Document Type: Review

References (31)

1. Jaovisidha K, Rosenthal AK: Calcium crystals in osteoarthritis. Curr Opin Rheumatol 2002, 14:298-302. This article provides a good overview with valuable referencing and discusses the roles for calcium crystals in osteoarthritis.
2. Cheung HS: The role of crystals in articular tissue degeneration. Curr Rheumatol Rep 1999, 1:128-131.
3. Mathew M, Takagi S: Crystal structures of calcium orthophosphates. Monogr Oral Sci 2001, 18:1-16. An extensive review of the chemistry of calcium phosphates is presented that provides insight into structure-related properties for biomineralization.
4. De Leeuw NH: Local ordering of hydroxyl groups in hydroxyapatite. J Chem Soc Chem Commun 2001, 17:1646-1647.
5. Pritzker KPH: Calcium pyrophosphate crystal formation and dissolution. In Calcium Phosphates in Biological and Industrial Systems. Edited by Amjad Z. Dordrecht: Kluwer Academic; 1997:277.
6. Rosenthal AK, Mandel N: Idenfification of crystals in synovial fluids and joint tissues. Curr Rheumatol Rep 2001, 3:11-16.
7. Brown EH, Lehr JR, Smith JP, et al.: Preparation and characterization of some calcium pyrophosphates. J Agri Food Chem 1963, 11:214.
8. Wierzbicki A, Sikes CS, Sallis JD, et al.: Scanning electron microscopy and molecular modeling of calcium oxafate monohydrate crystal growth inhibition by citrate and phosphocitrate. Calcif Tissue Int 1995, 56:297-304.
9. Sallis JD, Wierzbicki A, Cheung HS: Calcium pyrophosphate crystal salt forms and the influence of phosphocitrate. In Advances in Crystal Growth Inhibition Technologies. Edited by Amjad Z. New York: Kluwer Academic/Plenum; 2001:57-70. This study reports the alteration of crystal habit by phosphocitrate of various calcium pyrophosphate salt forms. It describes important chemical properties of phosphocitrate and demonstrates the power of molecular modeling.
10. Wierzbicki A, Cheung HS: Molecular modeling of inhibition of hydroxyapatite crystals by phosphocitrate. J Mol Structure Theochem 2001, 529:73-82. Changes that might be expected when phosphocitrate interacts with hydroxyapatite are discussed in a theoretical context and now require experimental evidence to confirm.
11. Bertoni E, Bigi A, Falini G, et al.: Hydroxyapatite/polyacrylic acid nanocrystals. J Mater Chem 1999, 9:779-782.
12. Kibalczyc W, Sokolowski T, Wiktorowska B: Calcium hydroxyapatite crystals grown in silica gel. Crystal Res Technol 1982, 17:105-106.
13. Mandel NS, Mandel GS, Carroll DJ, et al.: Calcium pyrophosphate crystal deposition. An in vitro study using a gelatin matrix model. Arthritis Rheum 1984, 27:789-796.
14. Sallis JD: Structure/performance relationships of phosphorous and carboxyl containing additives as calcium phosphate crystal growth inhibitors. In: Calcium Phosphates in Biological and Industrial Systems. Edited by Amjad Z. Norwell: Kluwer Academic; 1997:173-191.
15. Cheung HS: Phosphocitrate as a potential therapeutic strategy for crystal deposition disease. Curr Rheumatol Rep 2001, 3:24-28. This paper summarizes many of phosphocitrate's actions with respect to its hydroxyapatite and CPPD crystal-inhibiting ability. The potential to become a therapeutic agent for crystal deposition disease is discussed.
16. Nair D, Misra RP, Sallis JD, et al.: Phosphocitrate inhibits a basic calcium phosphate and calcium pyrophosphate dihydrate crystal-induced mitogen-activated protein kinase cascade signal transduction pathway. J Biol Chem 1997, 272:18920-18925.
17. Ryan LR: The ank gene story. Arthritis Res 2001, 3:77-79. Generation and delivery of pyrophosphate to enable crystallization are discussed. The unresolved questions posed are a stimulus inviting new research directions.
18. Yamakawa K, Iwasaki H, Masuda I, et al.: Cartilage intermediate layer protein expression in calcium pyrophosphate disease. J Reumatol 2002, 29:1746-1753.
19. Johnson K, Pritzker K, Goding J, et al.:The nucleoside triphosphate pyrophosphohydrolase isozyme PC-1 directly promotes cartilage calcification through chondrocyte apoptosis and increased calcium precipitation by mineralizing vesicles. J Rheumatol 2001, 28:2681-2691.
20. Masuda I, Hirose J: Animal models of pathologic calcification. Curr Opin Rheumatol 2002, 14:287-291.
21. Krug HE, Mahowald ML, Halverson PB et al.: Phosphocitrate prevents disease progression in murine progressive ankylosis. Arthritis Rheum 1992, 36:1603-1611.
22. Altman RD, Cheung HS: Synovial fluid basic calcium phosphate (BCP) crystals in an osteoarthritis (OA) canina model [abstract]. Osteoarthritis Cartilage 1997, 5:48.
23. Schumacher HR, Rubinow A, Rothfuss S, et al.: Apatite crystal clumps in synovial fluid are an early finding in canine arthritis [abstract]. Arthritis Rheum 1994, 37:S346.
24. Bendele AM, White SL, Hulman JF: Osteoarthritis in guinea pigs: Histopathologic and scanning electron microscopic features. Lab Anim Sci 1989, 39:115-121.
25. Lei W, Svensson O, Hjerpe A: Correlation of morphologic and biochemical changes in the histology of spontaneous OA in guinea pigs. Arthritis Rheum 1997, 40:2075-2083.
26. Kullich WC, Niksic F, Klein G: Effect of nimesulide on metalloproteinases and matrix degradation in osteoarthritis: a pilot clinical study. Int J Clin Pract Suppl 2002, 128:24-29.
27. Kumagai Y, Watanabe W, Kobayashi A, et al.: Inhibitory effect of low density lipoprotein in the inflammation inducing activity of calcium pyrophosphate dihydrate crystals. J Rheumatol 2001, 28:2674-2680. Low density lipoprotein by binding to crystals is considered an antiinflammatory agent. Because a rat air pouch model is used, it is difficult to consider that altering low density lipoprotein levels in humans would provide effective therapy.
28. Demadis KD, Sallis JD, Raptis RG, et al.: A crystallographically characterized nine-coordinated calcium-phosphocitrate complex as calcification inhibitor in vivo. J Am Chem Soc 2001, 123:10129-10130. A significant paper describes the formulation of a calcium-sodium phosphocitrate salt with more potent biologic activity than tetrasodium phosphocitrate.
29. Shinozaki T, Xu Y, Cruz TF, et al.: Calcium pyrophosphate dihydrate (CPPD) crystal dissolution by alkaline phosphatase: interaction of alkaline phosphatase on CPPD crystals. J Rheumatol 1995, 22:117-123.
30. Doherty M, Dieppe PA: Double blind, placebo controlled trial of magnesium carbonate in chronic calcium pyrophosphate arthropathy. Ann Rheum Dis 1983:42(suppl):106.
31. Shinozaki T, Pritzer KPH: Polyamines enhance calcium pyrophosphate dihydrate crystal dissolution J Rheumatol 1995, 22:1907-1912.